Our Experts

Name: Zifeng Wang
Title: Associate Professor
Email: wzifeng@mail.sysu.edu.cn
Phone: 020-87342713

Professor Zifeng Wang earned his Bachelor's and Doctoral degrees from the School of Life Sciences at Sun Yat-sen University. Subsequently, he conducted research on tumor occurrence and drug resistance mechanisms at the Chinese University of Hong Kong. In 2013, he was recruited into the Sun Yat-sen University Cancer Center under the prestigious "Hundred Talents Program" of the university. His primary research focus lies in the field of epigenetics. He employs cutting-edge techniques, including CRISPR library screening, ChIP-seq, ATAC-seq, Hi-C, and bioinformatics analysis, to investigate the intricacies of chromatin three-dimensional spatial organization and reconstruction. His ultimate goal is to unravel the mechanisms underlying changes in transcriptional and mutational landscapes during tumor progression. By doing so, he seeks to shed light on the causes of tumor occurrence and drug resistance, while also identifying potential biomarkers and therapeutic targets. 

Professor Zifeng Wang has made significant contributions to scientific literature, publishing research papers as the first or corresponding author in reputable journals such as Adv Sci, Signal Transduct Target Ther, Clin Cancer Res, Cancer Commun, Oncogene, Cell Death Dis, J Biol Chem, and Cancer Lett. He has been the recipient of three National Natural Science Foundation of China projects and two Guangdong Provincial Natural Science Foundation projects. Additionally, he has played a key role in the execution of a 973 Project and a Youth 863 Project. Moreover, Professor Wang holds five authorized patents.

He has been appointed as a youth member of the 9th Immunology Committee of the Chinese Society of Pathophysiology, and he actively participates in various professional committees, including the Antineoplastic Drug Professional Committee of the Guangdong Anti-Cancer Association, the Tumor Pharmacology Professional Committee of the Guangdong Pharmacological Society, and the Tumor Oncology Branch of the Guangdong Translational Medicine Society.


Cancer 3D genome and therapeutic targets


Ph.D., Sun Yat-sen University, China, 2008-2012

                    B.S., Sun Yat-sen University, China, 2004-2008


1. Liu F#, Wang X#, Duan J#, Hou Z#, Wu Z#, Liu L#, Lei H, Huang D, Ren Y, Wang Y, Li X, Zhuo J, Zhang Z, He B, Yan M, Yuan H, Zhang L, Yan J, Wen S*, Wang Z*, Liu Q*. A Temporal PROTAC Cocktail-Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells. Adv Sci (Weinh). 2022 Aug;9(22):e2104823. PMID: 35652200(IF:15.66)

2. Wang H#, Mei Y#, Luo C#, Huang Q#, Wang Z#, Lu GM, Qin L, Sun Z, Huang CW, Yang ZW, Chen J, Yin W, Qian CN, Zeng J, Chen L, Leng Q, Guo Y, Jia G*. Single-Cell Analyses Reveal Mechanisms of Cancer Stem Cell Maintenance and Epithelial-Mesenchymal Transition in Recurrent Bladder Cancer. Clin Cancer Res. 2021 Nov 15;27(22):6265-6278. PMID: 34526362(IF:12.53)

3. Xie J#, Wang Z#, Fan W#, Liu Y#, Liu F#, Wan X#, Liu M, Wang X, Zeng D, Wang Y, He B, Yan M, Zhang Z, Zhang M, Hou Z, Wang C, Kang Z, Fang W, Zhang L, Lam EW, Guo X, Yan J*, Zeng Y*, Chen M*, Liu Q*. Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma. Signal Transduct Target Ther. 2021 Sep 4;6(1):333. PMID: 34482361(IF:18.19)

4.Lei H#, Wang Z#, Jiang D#, Liu F#, Liu M, Lei X, Yang Y, He B, Yan M, Huang H*, Liu Q*, Pang J*. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer. Cell Death Dis. 2021 Jul 27;12(8):740. PMID: 34315855(IF:8.47)

5.Zhang Z#, Zeng D#, Zhang W#, Chen A#, Lei J, Liu F, Deng B, Zhuo J, He B, Yan M, Lei X, Wang S, Lam EW, Liu Q*, Wang Z*. Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition. Cell Death Dis. 2021 Sep 30;12(10):893. PMID: 34593753(IF:8.47)

6. Chen A#, Wen S#, Liu F, Zhang Z, Liu M, Wu Y, He B, Yan M, Kang T, Lam EW, Wang Z*, Liu Q*. CRISPR/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer. Cancer Commun (Lond). 2021 Feb;41(2):121-139. PMID: 33471959(IF:5.1)

7. Wang Z#, Lu G#, Sze J, Liu Y, Lin S, Yao H, Zhang J, Xie D, Liu Q, Kung HF, Lin MC, Poon WS. Plasma miR-124 Is a Promising Candidate Biomarker for Human Intracerebral Hemorrhage Stroke. Mol Neurobiol. 2018 Jul;55(7):5879-5888. (IF:5.59)

8. Zhang J#, Sai K#, Zhu ZQ#, Lin FH#, Wang ZF#, Chen YM#, Huang CY#, Ye YL#, Wang XL#, Li YP#, Sun SX#, Zhong WY#, Chen JB#, Yang YQ#. Prognostic factors for olfactory groove meningioma with nasal cavity extension. Oncotarget. 2017 Dec 19;9(4):4607-4613. PMID: 29435128 (IF:3.77)

9. Zhang J#, Al-Nahari F#, Wang Z#, Lin FH, Zhao YY, Xiao SY, Liu JM, Ke C, Chen ZH, Jiang Y, Yang M, Sai K, Wang J, Mou YG. Application of fluorescein sodium in the resection of vermis pilocytic astrocytomas. World J Surg Oncol. 2017 Feb 14;15(1):46. (IF:1.96)

10. Yang N#, Wang C#, Wang Z#, Zona S, Lin S, Wang X, Yan M, Zheng F Li S, Xu B, Bella L, Yong J, Lam E, Liu Q, FOXM1 recruits nuclear aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells, Oncogene. 2017 Jun 15;36(24):3428-3440. (IF:9.87) 

Updated by International Office, Sun Yat-sen University Cancer Center

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.